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INTRODUCTION
The hepatitis delta virus (HDV) is a defective RNA
virus dependent on Hepatitis B virus (HBV)
infection for its replication and expression .
Infection with HDV can occur simultaneously with
acute HBV infection (coinfection) or may be
superimposed on chronic infection (superinfection)
It is known that coexistent infection with HDV tends
to accelerate the progress of chronic HBV infection
to chronic hepatitis, cirrhosis and hepatocellular
carcinoma . Fulminant hepatitis may develop in 20-
30% of patients coinfected with HBV and HDV but
only about 2% of patients with HBV monoinfection
experience this complication . Sero-prevalence
studies in individuals positive for HBsAg show a
non- uniform worldwide distribution of HDV . The
regions of the world with highest prevalence of
HDV infection are the Mediterranean basin
including the Middle East, Eastern Europe, and
some regions of Asia . In Nigeria, the literature
is replete with studies on HBV infection in different
cohorts but not much is known about the
prevalence of HDV infection in patients with HBV-
related liver diseases. In Western Nigeria two
different studies on patients with chronic liver
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Some countries of the world have already recorded
declining trends in the occurrence of HDV infection
. The main objective of this study was to determine
the current seroprevalence of HDV antibody in
patients with various forms of HBV-related liver
disease at the University of Nigeria Teaching
Hospital, Ituku-Ozalla, Enugu, South Eastern
Nigeria.
This was a prospective, cross-sectional study of
consecutive patients with clinical features of liver
disease seen at the Gastroenterology Unit,
Department of Medicine, University of Nigeria
Teaching Hospital (UNTH) Ituku/Ozalla, between
April 2006 and September 2006. The study was
approved by the UNTH research ethics committee
and informed consent was obtained from all the
participants. Initial evaluation of the patients included
detailed history and thorough physical examination
with emphasis on the hepato-biliary system. Each
participant had his blood tested for Hepatitis B
surface antigen (HBsAg) with an enzyme-linked
immunosorbent assay (ELISA) kit that uses
polystyrene microwell strips pre-coated with
monoclonal antibodies specific to HBsAg. The test
has a sensitivity of 99.75% and specificity of 99.63%.
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Hepatitis D Virus (HDV) infection has been reported to be declining in some geographical areas. In
order to ascertain the current status of HDV infection in Nigeria, a study of patients with hepatitis B virus
(HBV)-related liver diseases was undertaken to determine the sero-prevalence of anti-HDV.
This was a prospective, cross-sectional study in which all consecutive patients with liver disease who
tested positive for Hepatitis B surface antigen (HBsAg) were also tested for antibody toHDV.
Ninety six patients with various forms of HBV-related liver diseases participated in the study (acute
hepatitis 8.3%, asymptomatic infection 15.6%, chronic hepatitis 3.1%, liver cirrhosis 21.9% and primary liver
cell carcinoma 51.0%).Anti-HDV was demonstrated in 12 patients (12.5%). In patients with acute hepatitis and
asymptomatic infection the prevalence was 4.3% while in patients with chronic hepatitis, liver cirrhosis and
primary liver cell carcinoma, the prevalence was 15%.
HDV still contributes to significant morbidity and mortality in HBV-related liver diseases in
Nigeria. There is urgent need for larger studies on a national scale to accurately appraise the public health
importance of this infection.
Hepatitis D Virus, Hepatitis B Virus, Sero-prevalence.
Liver Disease Anti – HDV
Positive
Acute Hepati tis, n = 8 0 (0)
Asymptomatic HBS Ag Positive, n = 15 1 (6.7)
Subtotal, n = 23 1(4.3)
Chronic Hepatitis, n = 3 0 (0)
Liver cirrhosis, n = 21 3 (14.3)
Hepatocellular carcinoma, n = 49 8 (16.3)
Subtotal, n = 73 11 (15.0)
Grand Total = 96 12 (12.5)
Table 1:Gender Distribution of Patients with HBV Related LiverDiseases.
Table 2:HDV Antibody in HB Related Liver Diseases.
RESULT
A total of 132 patients with various forms of liver
disease were screened for HBsAg. Ninety six of them
(72.7%) tested positive for HBsAg. These were made
up of 8 patients with acute hepatitis (8.3%), 15
patients with asymptomatic infection (15.6%), 3
patients with chronic hepatitis (3.1%), 21 patients
with liver cirrhosis (21.9%) and 49 patients with
primary liver cell carcinoma (51.0%). There were 77
males (80.2%) and 19 females (19.8%). Table 1
illustrates the gender distribution of patients with
various forms of HBV-related liver diseases. The
mean age of the patients was 41.14 18.21 years. The
mean age of the males was 42.04 18.96 years while
the mean age of the females was 37.58 14.81 years.
The difference between the mean ages of the male
and female patients was not statistically significant (p
= 0.3420). The mean age of patients who had acute
hepatitis and asymptomatic infection was 25.57
5.84 years while the mean age of patients with
chronic hepatitis, cirrhosis and primary liver cell
carcinoma was 46.26 17.99 years. The difference
between the means was statistically significant (p <
0.0001).Anti-HDV was demonstrated in 12 patients
(12.5%), made up of 10 males and 2 females. The






serum bilirubin (total and fractions), liver enzymes
(transaminases, and alkaline phosphatase), serum
protein (total and fractions), prothrombin time, full
blood count, urinalysis, abdominal ultrasonography
and where feasible, liver biopsy. Asymptomatic
individuals referred to the gastroenterology unit
after testing positive for HBsAg during screening for
blood donation or premarital testing were also
included and they underwent clinical evaluation and
laboratory tests as the other patients. Antibody to
HDV was tested for using ELISA kit for qualitative
determination of anti-HDV in human serum. The
test is based on solid phase, one step incubation
competitive ELISA, manufactured by Diagnostics
Automation, Inc. California USA. The sensitivity
and specificity approach 100%. Based on the
clinical features and results of the investigations the
patients were grouped into acute hepatitis,
asymptomatic HBV infection, chronic hepatitis,
liver cirrhosis and hepatocellular carcinoma.
The results were analyzed with the computer
program SPSS version 13 and expressed as means
and proportions. Where appropriate, differences
between proportions and means were determined
using the chi-square test and t-test. Statistical
significance was achieved if p= 0.05.
StatisticalAnalysis
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Liver Disease Male Female Total
Acute Hepatitis 6 2 8 (8.3)
Asymptomatic HB, Ag Positive 12 3 15 (15.6)
Chronic Hepatitis 3 - 3 (3.1)
Liver cirrhosis 16 5 21 (21.9)
Hepatocellular carcinoma 40 9 49 (51.0)
Total 77 (80.2) 19 (19.8) 96 (100)
Figures in parentheses = Percentages
Figures in parenthesis
= Percentages
for males and 10.5% for females. The difference was
not statistically significant (p=0.7590). Table 2
illustrates the anti-HDV sero-positivity in the
different forms of liver diseases. The prevalence of
anti-HDV was 0% in acute hepatitis, 6.7% in
asymptomatic infection, 0% in chronic hepatitis,
14.3% in liver cirrhosis and 16.3% in hepatocellular
carcinoma.The disease spectrum of HBV infection
can be grouped into early disease (acute hepatitis and
asymptomatic infection) and late infection (chronic
hepatitis, liver cirrhosis and hepatocellular
carcinoma). In this study the prevalence of anti-HDV
was 4.3% for early disease and 15.0% for late
infection. The difference between the proportions
was, however, not statistically significant (p=0.203)
The prevalence of anti-HDV in this study was 12.5%.
This cannot be compared directly with the studies in
Western Nigeria which showed lower prevalence.
The latter studies actually assayed HDV antigen
while this study assayed anti-HDV. Furthermore,
there have been reports of regional variability in
HDV prevalence in some parts of Africa and this
may also be operative in Nigerian patients. There is
need fore more studies to further elucidate this.
Advanced stages of HBV infection (liver cirrhosis
and primary cell carcinoma) accounted for about
73% of the patients with HBV-related liver diseases
who participated in this study. This is most likely
because of late presentation which is a major
problem in virtually all diseases encountered in
developing countries. Even when patients are
discovered at the stage of asymptomatic infection,
follow up is usually a problem, because they often
default and only reappear in hospital at a late stage
when the chances of cure are almost non existent.
This calls for concerted and sustained efforts at
health education of the populace on the need for
routine medical checks so that individuals with early
stages of the disease can be identified, followed up
and prompt interventions instituted as appropriate.
The gender-specific prevalence of HDV antibody in
this study was 13.0% in males and 10.5% in females.
The difference was not statistically significant. This
is different from what was observed in the Western
Brazilian Amazon where the prevalence is
significantly higher in males The prevalence of
anti-HDV in patients with late stages of HBV-related
liver diseases (chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma) was 15.0% compared to a
lower prevalence of 4.3% in patients with early
infection (acute hepatitis and asymptomatic
infection). Even though the difference was not
statistically significant, this might be an important
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rather than coinfection may be the dominant mode of
HDV infection in these patients. A higher prevalence
in the late stages of HBV-related liver disease was
also reported in a study in Turkey Some countries
have already recorded declining trends in the
occurrence of HDV infection This is sequel to
the introduction of childhood immunization against
HBV as part of national immunization programmes.
The same cannot be said to apply to most developing
countries due to belated or lack of introduction of
HBV vaccine in national immunization programmes
as well as poor sustainability of such programmes
In Nigeria, the absence of accurate statistical data on
the current magnitude of the problem of HDV
infection is likely to hamper effective surveillance of
this disease. This calls for larger studies on a national
scale so that our sub-region is not left out of the
current global efforts to stamp out liver diseases
caused by viruses.
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